CD274 and head and neck squamous cell carcinoma: <h4>Background</h4>For programmed death-ligand-1 (PD-L1) positive recurrent and metastatic head and neck squamous cell carcinoma (R/M-HNSCC), KEYNOTE-048 and KEYNOTE-040 clinical trials recently approved pembrolizumab monotherapy as first-line treatment.